Anticancer Activities of Mononuclear Ruthenium(II) Coordination Complexes
William M. Motswainyana,Peter A. Ajibade +1 more
- Vol. 2015, pp 1-21
TLDR
Ruthenium compounds are highly regarded as potential drug candidates as discussed by the authors, and they offer the potential of reduced toxicity and can be tolerated in vivo, however, they are not suitable for use in biological applications.Abstract:
Ruthenium compounds are highly regarded as potential drug candidates. The compounds offer the potential of reduced toxicity and can be tolerated in vivo. The various oxidation states, different mechanism of action, and the ligand substitution kinetics of ruthenium compounds give them advantages over platinum-based complexes, thereby making them suitable for use in biological applications. Several studies have focused attention on the interaction between active ruthenium complexes and their possible biological targets. In this paper, we review several ruthenium compounds which reportedly possess promising cytotoxic profiles: from the discovery of highly active compounds imidazolium [trans-tetrachloro(dmso)(imidazole)ruthenate(III)] (NAMI-A), indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)](KP1019), and sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) to the recent work based on both inorganic and organometallic ruthenium(II) compounds. Half-sandwich organometallic ruthenium complexes offer the opportunity of derivatization at the arene moiety, while the three remaining coordination sites on the metal centre can be functionalised with various coordination groups of various monoligands. It is clear from the review that these mononuclear ruthenium(II) compounds represent a strongly emerging field of research that will soon culminate into several ruthenium based antitumor agents.read more
Citations
More filters
Journal ArticleDOI
The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials
TL;DR: This review focuses on the likely mechanisms of action of ruthenium(ii)-based anticancer drugs and the relationship between their chemical structures and biological properties, and highlights the catalytic activity and the photoinduced activation of r Ruthenium (ii) complexes, their targeted delivery, and their activity in nanomaterial systems.
Antitumour metal compounds: more than theme and variations
Michael A. Jakupec,Markus Galanski,Vladimir B. Arion,Christian G. Hartinger,Bernhard K. Keppler +4 more
TL;DR: The recent achievement of oxaliplatin for the treatment of colon cancer should not belie the imbalance between a plethora of investigated complexes and a very small number of clinically approved platinum drugs.
Journal ArticleDOI
Metal complexes in cancer therapy - an update from drug design perspective.
TL;DR: It is optimistic that the concept of selective targeting remains the hope of the future in developing therapeutics that would selectively target cancer cells and leave healthy cells unharmed in cancer therapy.
Journal ArticleDOI
DNA binding properties, histidine interaction and cytotoxicity studies of water soluble ruthenium(II) terpyridine complexes
TL;DR: The results indicate that these complexes can bind to DNA covalently and non-covalently, and only compounds that hydrolyze the monodentate ligand at a reasonable rate show moderate activity.
Journal ArticleDOI
Editorial of Special Issue Ruthenium Complex: The Expanding Chemistry of the Ruthenium Complexes
TL;DR: Recent trends in Ru complex chemistry are surveyed with emphasis on the development of anticancer drugs and applications in catalysis, polymers, materials science and nanotechnology.
References
More filters
Journal ArticleDOI
Platinum Compounds: a New Class of Potent Antitumour Agents
TL;DR: The platinum compounds inhibit sarcoma 180 and leukaemia L1210 in mice and reversibly inhibit cell division in Gram-negative rods1–4.
Journal ArticleDOI
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
TL;DR: In E. coli, the presence of certain group VIIIb transition metal compounds in concentrations of about 1–10 parts per million of the metal in the culture medium causes an inhibition of the cell division process, which implies that the growth process is not markedly affected.
Journal ArticleDOI
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
TL;DR: The EPR-effect appears as a universal phenomenon in solid tumors which warrants the development of other polymeric drugs or nanomedicine, and then advantages and problems of macromolecular drugs.
Journal ArticleDOI
Journal of Molecular Structure: Special Issue: Organic Crystal Chemistry: Molecular Design, Structure, Reactivity, and Transformation-Proceedings of the 9th International Symposium on Organic Crystal Chemistry, Poznan-Rydzyna, Poland, 23–27 August, 1994, 374, 1996, Elsevier, Amsterdam, 396 pp
Journal ArticleDOI
New metal complexes as potential therapeutics.
TL;DR: Biological carriers conjugated to cisplatin analogs have improved specificity for tumor tissue, thereby reducing side effects and drug resistance, and metal-based chemotherapeutic compounds have the potential to modulate the biological properties of superoxide anion and nitric oxide.
Related Papers (5)
Classical and Non-Classical Ruthenium-Based Anticancer Drugs: Towards Targeted Chemotherapy
Wee Han Ang,Paul J. Dyson +1 more